Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany. (PubMed, Eur J Health Econ) - Feb 16, 2026 - "Our study demonstrated higher anti-CMV drug acquisition costs and overall direct treatment costs in patients receiving letermovir prophylaxis compared to controls. However, these higher costs are accompanied by significantly improved clinical outcomes."
HEOR • Journal • Real-world evidence • Cytomegalovirus Infection • Infectious Disease • Transplantation
|
|
Andrés R Rettig; Annika Y Classen; Claudia Wehr; Corinna Hebermehl; Daniel Teschner; Gesine Bug; Igor-Wolfgang Blau; J Janne Vehreschild; Maria J G T Vehreschild; Marie Engelhard; Olaf Penack; Sabrina Kraus; Sebastian M Wingen-Heimann; Sina M Pütz; Timo Schmitt; Torsten Steinbrunn
|